X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
LB-100 is a PP2A inhibitor which is being evaluated in phase 1/2 clinical trials in combination with Dostarlimab-gxly for the treatment of ovarian clear cell carcinoma.
Lead Product(s): LB-100,Dostarlimab
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2024
Details:
Under the terms of the license agreement, LIXTE will allow LB-100, which is a PP2A inhibitor with Dostarlimab for the treatment of Ovarian Clear Cell Carcinoma.
Lead Product(s): LB-100,Dostarlimab
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institute of Neurological Disorders and Stroke
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 26, 2024
Details:
LB-100 is a PP2A inhibitor which is being evaluated in phase 1/2 clinical trials in combination with Dostarlimab-gxly for the treatment of ovarian clear cell carcinoma.
Lead Product(s): LB-100,Dostarlimab
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2024
Details:
The expanded collaboration aims to study drug synergies of LIXTE’s lead clinical compound, LB-100, an inhibitor of the PP2A phosphatase, with immunotherapy in various cancers.
Lead Product(s): LB-100,Atezolizumab
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Netherlands Cancer Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration October 16, 2023
Details:
LB-100 is an inhibitor of PP2A, added to dostarlimab significantly increase the effectiveness of PD-1 immune-checkpoint blockade by activating cytotoxic T cells and CAR-T cells. It is being investegated for Clear-Cell Ovarian Cancer.
Lead Product(s): LB-100,Dostarlimab
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2023
Details:
The company intends to use the net proceeds for further clinical development of its first-in-class lead clinical PP2A inhibitor, LB-100, being developed in patients with low and intermediate-1 risk Myelodysplastic Syndrome (MDS).
Lead Product(s): LB-100
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alliance Global Partners
Deal Size: $3.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 20, 2023
Details:
LB-100 is an inhibitor of PP2A, added to doxorubicin significantly increase the effectiveness of PD-1 immune-checkpoint blockade by activating cytotoxic T cells and CAR-T cells. It is being investegated for advanced soft tissue sarcoma.
Lead Product(s): LB-100,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2023
Details:
LB-100 is an inhibitor of PP2A, added to doxorubicin significantly increase the effectiveness of PD-1 immune-checkpoint blockade by activating cytotoxic T cells and CAR-T cells. It is being investegated for advanced soft tissue sarcoma.
Lead Product(s): LB-100,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 24, 2023
Details:
LIXTE’s first-in-class protein phosphatase 2A (PP2A) inhibitor LB-100 with a standard regimen for previously untreated, extensive stage disease small cell lung cancer (ED-SCLC).
Lead Product(s): LB-100,Atezolizumab,Carboplatin
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2023
Details:
LB-100, an inhibitor of PP2A, significantly increase the effectiveness of PD-1 immune-checkpoint blockade by activating cytotoxic T cells and CAR-T cells. It has shown significant tumor shrinkage and the arrest of tumor progression in patients with advancing cancers.
Lead Product(s): LB-100,Atezolizumab,Carboplatin
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
Details:
LB-100, an inhibitor of PP2A, significantly increase the effectiveness of PD-1 immune-checkpoint blockade by activating cytotoxic T cells and CAR-T cells. It has shown significant tumor shrinkage and the arrest of tumor progression in patients with advancing cancers.
Lead Product(s): LB-100,Undisclosed
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2023
Details:
LB-100, a novel, first-in-class lead clinical compound and PP2A inhibitor, has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies, including cytotoxic drugs, radiation, and immune checkpoint blockers.
Lead Product(s): LB-100
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
Details:
The Company intends to use the net proceeds from the offering for working capital and general corporate expenses, including further clinical development of the Company’s lead compound LB-100.
Lead Product(s): LB-100
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: WestPark Capital
Deal Size: $5.8 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 14, 2022
Details:
CRISPR-based genetic screening and screening of selected investigational compounds both showed that LB-100 is synthetically lethal in combination with inhibitors of the mitotic entry kinase WEE1.
Lead Product(s): LB-100,Undiscloed
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Netherlands Cancer Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2022
Details:
The results belief that pharmacologic reduction of PP2A activity by administration of LB-100 will mimic the biological effects of inactivating mutations in the PPP2R1A gene, and therefore may be a general way to enhance immunotherapy.
Lead Product(s): LB-100
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2022
Details:
LB-100, a protein phosphatase (PP2A) inhibitor showed that models of colorectal, triple-negative breast and pancreatic cancer induces molecular changes that render the cancers more vulnerable to immunotherapy.
Lead Product(s): LB-100
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2022
Details:
LB-100 has been shown to enhance anti-cancer activity of standard chemotherapy and immunotherapy regimens against a broad spectrum of human cancers in animal models.
Lead Product(s): LB-100,Vosoritide
Therapeutic Area: Genetic Disease Product Name: LB-100
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 22, 2021
Details:
Phase 1b/2 clinical trial utilizes LB-100 as a single agent in the treatment of patients with low and intermediate-1 risk MDS, including patients with del(5q) myelodysplastic syndrome (del5qMDS) failing first line therapy.
Lead Product(s): LB-100,Carboplatin,Etoposide
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: City of Hope
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2021
Details:
In the Phase 1b trial of LB-100 for the treatment of ED-SCLC, Lixte’s lead compound will be given in combination with carboplatin, etoposide and atezolizumab, an FDA approved but marginally effective regimen, in previously untreated ED-SCLC.
Lead Product(s): LB-100,Carboplatin,Etoposide
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: City of Hope
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2021
Details:
The company intends to use the net proceeds from the offering for working capital and general expenses including further development of its lead clinical compound LB-100.
Lead Product(s): LB-100
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: WestPark Capital
Deal Size: $4.1 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 01, 2021
Details:
The trial will assess the combination of Lixte’s first-in-class protein phosphatase inhibitor LB-100 with a standard regimen for untreated, extensive stage-disease small cell lung cancer (ED-SCLC).
Lead Product(s): LB-100,Atezolizumab,Carboplatin
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: City of Hope
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 19, 2021
Details:
Collaboration will support the preclinical studies of the potential benefit of Lixte’s proprietary lead clinical compound, LB-100, in a mouse model of Angelman Syndrome (AS).
Lead Product(s): LB-100
Therapeutic Area: Genetic Disease Product Name: LB-100
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lixte Biotechnology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 18, 2020
Details:
LB-100, enhanced pharmacological immunotherapy of intracranial brain tumors in immune-competent mice including 25% complete regression and immunity to tumor rechallenge.
Lead Product(s): LB-100
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
